Vidac Pharma completes enrollment in Phase 2B study of VDA-1102

Vidac Pharma has finished enrolling all 39 patients in its Phase 2B study of VDA-1102 for high-risk actinic keratosis, keeping the trial on its projected timeline. Follow-up continues for about three months, with topline results expected after database lock and data analysis.

Why it matters: - The enrollment milestone moves Vidac Pharma one step closer to topline data for VDA-1102 in high-risk actinic keratosis. - The study could help shape the outlook for the company’s lead drug candidate in oncology and onco-dermatology. - No treatment-related serious adverse events have been reported to the company so far, which is an important safety signal, though the full dataset is still pending.

What happened: - Vidac Pharma completed patient enrollment in its Phase 2B clinical study of VDA-1102 after enrolling the final patient on 11 June 2026. - The randomized study enrolled all 39 planned patients. - The trial is testing VDA-1102 in high-risk actinic keratosis. - Follow-up remains ongoing.

The details: - VDA-1102 is Vidac Pharma’s lead drug candidate and a proprietary small-molecule therapy. - The program targets altered cancer metabolism through modulation of the Hexokinase-2, or HK2, pathway. - Patient follow-up is expected to continue for about three months after the last patient was enrolled. - Vidac Pharma expects to report topline results after follow-up is complete, the database is locked and the data are analyzed. - The company said enrollment was completed within the projected timeline it had previously communicated. - The company said no conclusions on efficacy or safety can be drawn until the study is complete and the full dataset is analyzed.

Between the lines: - Enrollment completion is an operational milestone, not a readout, so investor focus now shifts to follow-up and the eventual data package. - The lack of reported treatment-related serious adverse events to date may support confidence in the trial, but the company has not released final safety or efficacy results. - The study sits within Vidac Pharma’s broader push in oncology and onco-dermatology.

What’s next: - Vidac Pharma will finish patient follow-up over the next roughly three months. - The company will then complete database lock and data analysis. - Topline results are expected after those steps are finished. - Vidac Pharma may also continue advancing its broader clinical development program in oncology and onco-dermatology.

The bottom line: - Vidac Pharma has cleared a key enrollment hurdle for VDA-1102, but the meaningful test comes next when the company turns follow-up data into results.